Catalio Capital Management
Catalio Capital Management is a New York-based investment firm managing $2B in assets across private equity, structured credit, public equities, and co-investments, serving institutional limited partners with specialist healthcare exposure sourced from a 45+ scientist-entrepreneur Venture Partner network.
- Company typePrivate
- Founded2020
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Catalio Capital Management does
Catalio Capital Management is a New York-based investment firm specializing in innovative healthcare companies across the full investment lifecycle — private equity, structured credit, public equities, and co-investments. Founded in 2020 by Johns Hopkins alumni George C. Petrocheilos and R. Jacob Vogelstein, Ph.D., the firm serves institutional limited partners and family offices seeking specialist healthcare exposure. As of October 1, 2025, Catalio reported $2 billion in assets under management, with $2.3 billion in healthcare assets under management within its public equities strategy, and has distributed nearly $300 million to investors since 2020 in a market where 79% of venture capital funds raised since 2020 reportedly returned $0 to investors. The firm employs 40+ people across offices in New York City, Washington DC, and London, with Asia coverage led by Partner Hai Yan, Ph.D. in Singapore. KKR acquired a minority stake in October 2023, and KKR Co-Founder Henry Kravis serves as Chairman of Catalio's Board of Advisors.
The firm's investment platform comprises four core strategies: Private Equity (venture capital) backing innovative drugs, AI-enabled companies, medical devices, and diagnostics; Structured Opportunities (structured credit) targeting commercial-stage healthcare companies with $10M–$50M deals; Public Equities (a healthcare-focused public fund launched in 2023); and Co-Investments. Catalio's primary differentiator is a proprietary expert network of 45+ scientist-entrepreneur Venture Partners — including Nobel laureates Jim Allison, Thomas Südhof, Gregg Semenza, Frances Arnold, and Adam Riess — collectively credited with founding 171 companies and holding 12 Nobel and Breakthrough Prizes. The firm is building human-augmented investment platforms powered by a newly created data-science function led by a former Citadel/Coatue executive, applying AI to support investing across private, public, and credit healthcare markets.
Catalio generates revenue through traditional private-fund economics: management fees on committed/invested capital across multiple vehicles — including the ~$400M Fund IV, the $325M Structured Opportunities Fund II, and the public equities fund — plus performance-based carried interest. Distribution combines direct institutional private placement to LPs with separately managed accounts, most notably a $200 million allocation from macro hedge fund Brevan Howard in June 2026. Materials are reserved for financially sophisticated investors and distributed via password-protected SEI and MSFS investor portals under Securities Act private placement exemptions; the firm is not registered with the SEC as an investment adviser.
Catalio Capital Management firmographics
Firmographics- Name
- Catalio Capital Management
- Legal name
- Catalio Capital Management, LP
- Website
- https://cataliocapital.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Catalio Capital Management is a New York-based investment firm managing $2B in assets across private equity, structured credit, public equities, and co-investments, serving institutional limited partners with specialist healthcare exposure sourced from a 45+ scientist-entrepreneur Venture Partner network.
- Ownership category
- akta.pro rank
Catalio Capital Management industry classification
Industry- Product category
- Healthcare Investment Management
- NAICS
- Portfolio Management and Investment Advice (523940), Other Financial Vehicles (525990)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Catalio Capital Management is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Catalio Capital Management business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure, Others
Revenue model
- Fund Management Fees & Carried Interest: Catalio generates revenue through traditional private-fund economics: management fees on committed/invested capital across multiple vehicles (including Private Equity funds, Structured Opportunities Fund II, Fund IV) plus performance-based carried interest on investment gains. The firm has distributed nearly $300M to investors from its Funds and SPVs over the period since 2020.
- Separately Managed Accounts (SMAs): Execution-style SMA mandates (e.g., Brevan Howard's $200M allocation into Catalio's healthcare-focused public equities fund) where Catalio executes trades while the client retains risk controls — generating fee revenue without balance-sheet exposure.
- Structured Credit Interest & Fees: Targeted structured credit investments ($10M–$50M deals) into commercial-stage healthcare companies, generating interest income and structuring fees as an alternative to dilutive equity financing; the strategy has completed 21 investments to date.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Private placement fund terms — not publicly disclosed |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels5 records
Catalio Capital Management product offering
Product offeringCore offering
Catalio Capital Management is a New York-based investment firm that manages capital across the full lifecycle of innovative healthcare companies, spanning private equity (venture capital), structured credit opportunities, public equities, and co-investments. The firm raises capital from institutional limited partners and family offices via private placement of dedicated fund vintages, deploying that capital into drugs, AI-enabled healthcare, devices, diagnostics, and related biomedical technology companies. Investment decisions are supported by a proprietary network of 45+ scientist-entrepreneur Venture Partners who provide deal flow and scientific due diligence.
Product overview
Catalio Capital Management is a New York-based investment firm (not a traditional technology product company) that offers a platform of four core investment strategies under one unified firm: Private Equity (Venture Capital), Structured Opportunities, Public Equities, and Co-Investments. These strategies work together to provide full lifecycle healthcare investing across private, public, and credit markets, with $2B+ in assets under management, 40+ employees, 45+ Venture Partners, and a portfolio spanning drugs, AI-enabled companies, devices, diagnostics, and other healthcare categories. While Catalio's offerings are investment strategies rather than software products, the firm is building AI-augmented investment platforms internally to support its portfolio analysis and due diligence processes.
Differentiator
Problem solved
Functional benefit
Brands
- Catalio Venture Partners: Network of 45+ world-renowned scientist-entrepreneurs who serve as Catalio's proprietary expert network for scientific due diligence and provide differentiated insight, specialized expertise across sectors, and extensive track record of success.
- Catalio Structured Opportunities Fund
Products and services
- Private Equity (Venture Capital) Flagship venture capital strategy investing in innovative healthcare companies across drugs, AI-enabled companies, devices, diagnostics, and other categories; portfolio includes Arrivent, ATAI Life Sciences, Compass, Dianthus, Recursion, Neumora, and others across the full healthcare lifecycle. For institutional limited partners.
- Structured Opportunities Structured credit strategy targeting commercial-stage healthcare companies seeking structured capital as an alternative to dilutive equity financing; Catalio Structured Opportunities Fund II raised more than $325M, exceeding its $250M target, and has completed 21 investments to date. For institutional limited partners.
- Public Equities Healthcare-focused public equities fund managing $2.3 billion in healthcare assets spanning pharmaceuticals, medical devices, diagnostics, and data companies; has delivered a 49% net return since its 2023 launch. For institutional limited partners and multi-manager platforms.
- Co-Investments Co-investment strategy providing investors with opportunities to participate alongside Catalio's lead investments in innovative healthcare companies across all stages and sizes throughout the capital structure. For institutional limited partners.
- Separately Managed Accounts (SMAs) Execution-style separately managed account mandates where Catalio executes trades on a healthcare-focused public-equities strategy while the institutional client retains risk controls; generates fee revenue without balance-sheet exposure. For multi-manager hedge fund platforms.
Quantifiable outcome
- 49% net return on healthcare-focused public equities fund since its 2023 launch
- +5 more outcomes
Companies that use Catalio Capital Management
Customer profileSegments3 records
Ideal customer profiles3 records
Catalio Capital Management technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Catalio Capital Management partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship.
- Henry Kravis (Co-Founder & Co-Chairman, KKR & Co.)flagshipHenry Kravis serves as Chairman of Catalio's Board of Advisors. The board includes other marquee institutional figures including Orlando Bravo (Founder & Managing Partner, Thoma Bravo), Jim Breyer (Founder & CEO, Breyer Capital), Michael Buckley (Managing Director, Duquesne Family Office), Glenn Dubin (Founder & Principal, Dubin & Co.), Isabelle Ealet (Partner & Co-Head, Securities Division, Goldman Sachs), Alex Gorsky (Chairman & CEO Retired, Johnson & Johnson), and Tim O'Neill (Partner & Co-Head of Goldman Sachs Asset Management Ret.).
- Catalio Venture Partner Network (45+ scientist-entrepreneurs)flagshipNetwork of 45+ world-renowned, serial scientist-entrepreneurs who provide proprietary deal flow, scientific due diligence, advisory on emerging biomedical trends, and sector-specialized expertise. The collective network has founded 171 companies and holds 12 Nobel & Breakthrough Prizes, with members including Nobel laureates Jim Allison (immunology), Thomas Südhof (neuroscience), Gregg Semenza (oxygen biology), Frances Arnold (chemistry), Adam Riess (physics), and Turing Award-related figures.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Catalio Capital Management competitors and assessment
Company assessmentDirect peers
- OrbiMed Advisors: OrbiMed is a healthcare-dedicated investment firm investing across private equity, public equity, and royalty/credit vehicles — directly comparable to Catalio's full-lifecycle, full-capital-structure healthcare platform and similar sector focus.
- RA Capital Management: RA Capital is a healthcare-focused multi-stage fund manager that runs both private and public equities strategies — closely mirroring Catalio's combination of healthcare PE and a 49%-returning public equities fund.
- ARCH Venture Partners: ARCH is a long-tenured life sciences and breakthrough-technology venture firm with a scientist-founded model, directly comparable to Catalio's emphasis on Nobel-grade scientific Venture Partners and breakthrough biomedical deal flow.
- Versant Ventures: Versant is a healthcare-focused venture capital firm operating across stages, including a dedicated credit/structured capital arm — directly comparable to Catalio's PE + Structured Opportunities + Co-Investments platform.
- Atlas Venture: Atlas Venture is an early-stage life sciences-focused venture firm building biotech companies, comparable to Catalio's life sciences venture strategy and its Venture-Partner-led company-creation model.
- Flagship Pioneering: Flagship Pioneering is a science-driven venture creation firm that founds and funds breakthrough biomedical companies, comparable to Catalio's biomedical specialization and its scientist-entrepreneur network-led origination.
- 5AM Ventures: 5AM Ventures is a life sciences-focused venture capital firm investing across early and late stages in biotech and medtech — directly comparable to Catalio's stage-agnostic healthcare venture strategy.
- Cormorant Asset Management: Cormorant is a healthcare-focused investment manager running long/short public equities with private/venture exposure, closely mirroring Catalio's specialist healthcare public-equities plus private investment approach.
- Baker Bros. Advisors: Baker Bros. is a long-tenured, healthcare-only specialist managing both long-only public equities and private investments, directly comparable to Catalio's healthcare-specialist, multi-strategy model.
Broad incumbents
- New Enterprise Associates (NEA): NEA is a large, multi-sector venture capital firm with a substantial healthcare practice — comparable to Catalio on healthcare investing but with a much broader sector mandate and far larger AUM.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Catalio Capital Management social profiles
Digital presenceCatalio Capital Management financial estimates
Financial estimateRevenue estimate
Valuation estimate
Catalio Capital Management leadership team
Management profileNumber of profiles
Profiles32 records
Catalio Capital Management subsidiaries and ownership
Company hierarchySubsidiaries2 records
Catalio Capital Management funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Catalio Capital Management M&A and investment
M&A and investmentM&A2 records
Investments150 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Catalio Capital Management
What does Catalio Capital Management do?
Catalio Capital Management is a New York-based investment firm that manages capital across the full lifecycle of innovative healthcare companies, spanning private equity (venture capital), structured credit opportunities, public equities, and co-investments. The firm raises capital from institutional limited partners and family offices via private placement of dedicated fund vintages, deploying that capital into drugs, AI-enabled healthcare, devices, diagnostics, and related biomedical technology companies. Investment decisions are supported by a proprietary network of 45+ scientist-entrepreneur Venture Partners who provide deal flow and scientific due diligence.
Is Catalio Capital Management a public or private company?
Catalio Capital Management is a private company. It is classified as venture growth investor backed and is currently operating.
When was Catalio Capital Management founded?
Catalio Capital Management was founded in 2020. It employs 11 to 50 people.
Where is Catalio Capital Management based?
Catalio Capital Management is headquartered in New York, United States, in the North America region.
How does Catalio Capital Management make money?
Three revenue lines are on record. Fund Management Fees & Carried Interest is the primary driver. The others are separately Managed Accounts (SMAs) and structured Credit Interest & Fees.
Who are Catalio Capital Management's main competitors?
Direct peers on record are OrbiMed Advisors, RA Capital Management, ARCH Venture Partners, Versant Ventures, Atlas Venture, Flagship Pioneering, 5AM Ventures, Cormorant Asset Management and Baker Bros. Advisors. New Enterprise Associates (NEA) is listed as a broad incumbent.
Does Catalio Capital Management have an API?
No public API is recorded for Catalio Capital Management.
What industry is Catalio Capital Management in?
Catalio Capital Management's product category is Healthcare Investment Management. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.